Attached files

file filename
8-K - 8-K FILING - PRO DEX INCf16-0833.htm

 

Exhibit 99.1

 

 

Contact: Richard L. Van Kirk, Chief Executive Officer

(949) 769-3200

For Immediate Release

 

PRO-DEX, INC. ANNOUNCES FISCAL 2016

FOURTH QUARTER AND FULL-YEAR RESULTS

 

IRVINE, CA, September 15, 2016 - PRO-DEX, INC. (NasdaqCM: PDEX) today announced financial results for its fiscal 2016 fourth quarter and full-year ended June 30, 2016.

 

Quarter Ended June 30, 2016

 

Net sales for the three months ended June 30, 2016 increased $1.2 million, or 29%, to $5.3 million from $4.1 million for the three months ended June 30, 2015, due primarily to increased medical device sales, especially in the orthopedic and craniomaxillofacial (“CMF”) surgical segments. Gross profit for the three months ended June 30, 2016 increased $311,000, or 27%, to $1.4 million from $1.1 million for the same period in 2015. Contributing to this increase was the increase in sales volume, described above.

 

Operating expenses (which include selling, general and administrative, and research and development expenses) for the quarter ended June 30, 2016 increased 17% to $1.2 million from $1.1 million in the prior year’s corresponding quarter, reflecting primarily our increase in research and development costs as we have increased our personnel in support of our increased medical device products and ongoing engineering development projects.

 

Income from continuing operations for the quarter ended June 30, 2016 increased by $116,000 to $189,000, compared to $73,000 in the corresponding quarter in 2015. Net income for the quarter ended June 30, 2016 was $189,000, or $0.05 per share, compared to net income of $73,000, or $0.02 per share, for the corresponding quarter in 2015.

 

Year Ended June 30, 2016

 

Net sales for the year ended June 30, 2016 increased $6.8 million, or 51%, to $20.1 million from $13.3 million for the year ended June 30, 2015, due primarily to increases in medical device revenues. Specifically, our largest customer accounted for an increase of $4.5 million in revenue during the current fiscal year. Additionally, sales relating to two CMF surgical drivers which we developed to the unique specifications of our customers contributed to an increase in sales of $3.6 million. Offsetting these increases, sales to our former largest customer in the medical device segment decreased by approximately $3.0 million from $6.6 million to $3.6 million..

 

Gross profit for the year ended June 30, 2016 increased $1.7 million, or 46%, to $5.4 million compared to $3.7 million for the same period in 2015.

 

Operating expenses (which include selling, general and administrative, and research and development expenses) for the year ended June 30, 2016 increased 6% to $4.8 million from $4.6 million in the prior fiscal year, reflecting primarily the $245,000 impairment charge we recorded related to our Fineline Molds division as a result of our annual impairment test.

 

   

 

 

Income from continuing operations for the year ended June 30, 2016 was $822,000, compared to a loss from continuing operations of $402,000 for fiscal 2015. Net income for the year ended June 30, 2016 was $822,000, or $0.20 per share, compared to a net loss of $365,000, or $0.09 per share, for fiscal 2015.

 

During the year ended June 30, 2016, the Company provided $446,000 of cash in operating activities, compared to the use of $775,000 of cash used in operating activities in fiscal 2015. The increase in cash provided by operating activities is primarily due to our return to profitability and is offset by reduced trade related payables which had accumulated at June 30, 2015, due to inventory purchases in anticipation of new product releases. During the year ended June 30, 2016, we also liquidated our investment in the Riverside property and related notes receivable and collected $2.0 million as a result of that liquidation and recorded a gain related to the liquidation in the amount of $340,000.

 

In June 2016, we received a contractual commitment from our largest customer to deliver 1,800 surgical handpieces in both calendar 2017 and 2018. This purchase commitment is valued at approximately $24 million and we expect to see increased sales and margins in the second half of fiscal 2017 as a result of beginning delivery on this order. During the first half of fiscal 2017, we will be delivering 500 handpieces to this same customer at a reduced sales price, which will consequently reduce margins.

 

CEO Comments

 

Richard L (“Rick”) Van Kirk, the Company’s President and Chief Executive Officer, commented, “We are pleased with our fourth quarter and full year operating results as we return to consistent profitability. We are also encouraged by the sales commitment from our largest customer, which will provide our production facility with a consistent base level of operations. We will also continue to focus efforts on completion of another product development project and continue to meet the needs of our growing customer base in the area of engineering and manufacturing expertise for handheld surgical devices for orthopedic, neurological and other applications. We anticipate another profitable year in fiscal 2017.”

 

About Pro-Dex, Inc.:

 

Pro-Dex, Inc., with operations in California and Oregon, specializes in the design, development and manufacture of powered rotary drive surgical and dental instruments used primarily in the orthopedic, spine, maxocranial facial and dental markets.  Its OMS division designs and manufactures embedded motion control systems serving the medical, factory automation, semi-conductor and scientific research markets. Its Fineline Molds division manufactures plastic injection molding for a variety of industries. Pro-Dex’s products are found in hospitals, dental offices, medical engineering labs, scientific research facilities and high tech manufacturing operations around the world.

 

Pro-Dex also provides quality and regulatory consulting services, as well as engineering consulting and placement services through its Engineering Services Division.  For more information, visit the Company’s website at www.pro-dex.com.

 

Statements herein concerning the Company’s plans, growth and strategies may include ‘forward-looking statements’ within the context of the federal securities laws. Statements regarding the Company’s future events, developments and future performance, as well as management’s expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. The Company’s actual results may differ materially from those suggested as a result of various factors. Interested parties should refer to the disclosure concerning the operational and business concerns of the Company set forth in the Company’s filings with the Securities and Exchange Commission.

 

(tables follow)

 

   

 

 

PRO-DEX, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(In thousands, except share data)

 

   June 30,
   2016  2015
ASSETS          
Current assets:          
Cash and cash equivalents   $2,294   $697 
Accounts receivable, net of allowance for doubtful accounts of $20 and $36    1,469    2,326 
Due from factor    1,419     
Deferred costs    238    853 
Other current receivables    91    28 
Inventory    3,573    4,310 
Prepaid expenses    134    124 
Deferred income taxes        70 
Total current assets    9,218    8,408 
Plant, equipment and leasehold improvements, net    1,286    1,470 
Investment in Ramsey property and related notes receivable        1,652 
Goodwill    112    353 
Intangibles    451    547 
Other assets    80    86 
Total assets   $11,147   $12,516 
           
LIABILITIES AND SHAREHOLDERS’ EQUITY          
Current liabilities:          
Accounts payable   $841   $1,867 
Accrued liabilities    997    1,202 
Deferred revenue    212    594 
Income taxes payable    1     
Note payable    26    24 
Capital lease obligations        7 
Total current liabilities    2,077    3,694 
Non-current liabilities:          
Deferred income taxes        70 
Deferred rent    147    204 
Note payable, net of current portion    46    70 
Capital lease obligations, net of current portion         
Total non-current liabilities    193    344 
Total liabilities    2,270    4,038 
           
Shareholders’  equity:          
Common stock, no par value, 50,000,000 shares authorized; 4,052,987 and 4,139,579 shares issued and outstanding at June 30, 2016 and 2015, respectively    17,988    18,411 
Accumulated other comprehensive income         
Accumulated deficit    (9,111)   (9,933)
Total shareholders’ equity    8,877    8,478 
Total liabilities and shareholders’ equity   $11,147   $12,516 

 

   

 

 

PRO-DEX, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share data)

 

   Three Months Ended
June 30,
(Unaudited)
  Years Ended
June 30,
   2016  2015  2016  2015
Net sales   $5,285   $4,073   $20,158   $13,383 
Cost of sales    3,840    2,939    14,775    9,679 
Gross profit    1,445    1,134    5,403    3,704 
                     
Operating expenses:                    
Selling expenses    233    285    898    975 
General and administrative expenses    476    420    1,882    1,963 
Impairment of goodwill and intangible assets            245     
Research and development costs    538    359    1,852    1,668 
Total operating expenses    1,247    1,064    4,877    4,606 
                     
Operating profit (loss)    198    70    526    (902)
Interest expense    (1)   (2)   (37)   (6)
Interest income                6 
Gain (loss) from disposal of equipment            18    1 
Gain from sale of Investment in Ramsey Property            340     
Realized gain on sale of investments                455 
                     
Income (loss) from continuing operations before income taxes    197    68    847    (446)
Income tax expense (benefit)    9    (5)   25    (44)
                     
Income (loss) from continuing operations    189    73    822    (402)
Income from discontinued operations, net of income taxes               37 
Net income (loss)   $189   $73   $822   $(365)
                     
Basic and diluted net income (loss) per share:                    
Income (loss) from continuing operations   $0.05   $0.02   $0.20   $(0.10)
Income from discontinued operations                0.01 
Net income (loss)   $0.05   $0.02   $0.20   $(0.09)
                     
Weighted average shares outstanding:                    
Basic    4,131,076    4,139,579    4,141,353    4,169,326 
Diluted    4,177,439    4,152,811    4,173,556    4,169,326 

 

   

 

 

PRO-DEX, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

 

   Years Ended June 30,
   2016  2015
CASH FLOWS FROM OPERATING ACTIVITIES:          
Net income (loss)   $822   $(365)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:          
Depreciation and amortization    614    578 
Realized gain on sale of investments        (455)
Gain on sale of investment in Ramsey    (340)    
Gain on sale or disposal of equipment    (18)   (1)
Impairment of goodwill and intangible assets    245     
Share-based compensation    4    17 
Allowance for doubtful accounts    (16)   7 
Changes in operating assets and liabilities:          
Accounts receivable, due from factor and other current receivables    (523)   (554)
Unbilled receivables    615    220 
Inventory    737    (1,705)
Prepaid expenses and other assets    (5)   (22)
Accounts payable, accrued expenses and deferred rent    (1,288)   1,196 
Deferred revenue    (382)   362 
Income taxes receivable and payable    1    (53)
Net cash provided by (used in) operating activities    466    (775)
           
CASH FLOWS FROM INVESTING ACTIVITIES:          
Purchases of equipment and leasehold improvements    (311)   (244)
Business acquisitions        (866)
Purchase of notes receivable        (1,652)
Investment in Ramsey and related note receivable    (87)    
Proceeds from of investment in Ramsey    1,992     
Proceeds from sale of equipment    18    1 
Proceeds from sale of investments        1,324 
Increase in intangibles    (24)   (64)
Purchase of investments        (12)
Net cash provided by (used in) investing activities    1,588    (1,513)
           
CASH FLOWS FROM FINANCING ACTIVITIES:          
Principal payments on capital lease and note payable    (530)   (15)
Proceeds from note payable    500     
Borrowings from Summit loan    1,689     
Repayments on Summit loan    (1,689)    
Repurchase of common stock    (454)   (154)
Net proceeds received (paid) related to common stock rights offering        (2)
Proceeds (payments) from exercise (repurchase) of stock options and ESPP contributions   27    (32)
Net cash provided by (used in) financing activities    (457)   (203)
           
Net increase (decrease) in cash and cash equivalents    1,597    (2,491)
Cash and cash equivalents, beginning of year    697    3,188 
Cash and cash equivalents, end of year   $2,294   $697